Associations between selected fastidious bacterial vaginosis-associated bacteria (BVAB)*, ureaplasmal bacteria and histologically confirmed endometritis† 30 days following treatment for pelvic inflammatory disease
| Endometritis†+ n=175 n/N (%) | Endometritis†− n=238 n/N (%) | Adjusted RR‡ (95% CI) | |
|---|---|---|---|
| BVAB (1 or more +)* | |||
| Cervix and/or endometrium | 149/175 (85.1) | 199/238 (83.6) | 1.1 (0.6 to 2.2) |
| Endometrium | 111/169 (65.7) | 140/234 (59.8) | 1.2 (0.7 to 2.0) |
| BVAB (all positive)* | |||
| Cervix and/or endometrium | 37/63 (58.7) | 32/71 (45.1) | 2.3 (0.9 to 5.9) |
| Endometrium | 11/69 (15.9) | 5/99 (5.1) | 5.7 (1.4 to 23.3) |
| Ureaplasma urealyticum | |||
| Cervix and/or endometrium | 40/167 (24.0) | 49/231 (21.2) | 1.0 (0.5 to 1.7) |
| Endometrium | 15/170 (8.8) | 11/235 (4.7) | 1.7 (0.6 to 4.3) |
| Ureaplasma parvum | |||
| Cervix and/or endometrium | 69/169 (40.8) | 70/234 (29.9) | 1.9 (1.2 to 3.2) |
| Endometrium | 27/170 (15.9) | 31/235 (13.2) | 2.0 (1.0 to 3.9) |
*Sneathia sanguinegens, Sneathia amnionii, Atopobium vaginae and BVAB1. Comparison group consists of women who tested negative for all four bacteria. In model of ‘all positive’, women testing positive for some but not all bacteria are excluded.
†≥5 surface epithelium neutrophils per ×400 field absent of menstrual endometrium and/or ≥2 stromal plasma cells per ×120 field.
‡Adjusted for age, race and self-reported partner treatment.